A statement released earlier today by Vetr Inc. about Celgene Corporation (NASDAQ:CELG) raises the target price to $122.94
- Updated: September 22, 2016
Yesterday Celgene Corporation (NASDAQ:CELG) traded 0.90% higher at $110.98. The company’s 50-day moving average is $109.92 and its 200-day moving average is $105.10. The last stock close price is up 5.21% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 4,458,373 shares of the stock were exchanged, up from an average trading volume of 4,292,700
Celgene Corporation (NASDAQ:CELG) had its target price bumped up to $122.94 by Vetr Inc. in a report issued 09/22/2016. The new target price implies a potential upside of 0.11% from the company's most recent stock close price.
Previously on 8/30/2016, Vetr Inc. reported about Celgene Corporation (NASDAQ:CELG) raised the target price from $0.00 to $120.45. At the time, this indicated a possible upside of 0.12%.
See Chart Below
Celgene Corporation has a 52 week low of $93.05 and a 52 week high of $128.39 with a PE ratio of 46.73 Celgene Corporation’s market capitalization is currently $0.
In addition to Vetr Inc. reporting its stock price target, a total of 22 brokers have issued a research note on the company. The average stock price target is $136.82 with 10 brokers rating the stock a strong buy, 10 brokers rating the stock a buy, four analysts rating the company a hold, one analyst rating the company a underperform, and lastly zero analysts rating the company a sell.
General Company Details For Celgene Corporation (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.